Compounds useful in modulating the farnesoid X receptor and methods of making and using the same
申请人:Inorbit Therapeutics AB
公开号:US11339153B2
公开(公告)日:2022-05-24
Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR such as bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, kidney disorders (including chronic kidney disease), hepatic and colon cancers, and other disorders. The compounds are in the class of sulfinic acid compounds and can be an enantiomer, stereoisomer, tautomer, solvate, hydrate, prodrug, metabolite, or pharmaceutically acceptable salt thereof. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
本发明提供了可作为法尼类固醇 X 受体(FXR)调节剂的化合物,这些化合物可用于治疗与 FXR 相关的疾病和/或紊乱,如胆汁酸相关紊乱、代谢综合征、2 型糖尿病、高脂血症、高甘油三酯血症、原发性胆汁性肝硬化(PBC)、脂肪肝、非酒精性脂肪性肝炎(NASH)、炎症性自身免疫性疾病、克罗恩病、多发性硬化症、原发性胆汁性肝硬化(PBC)、脂肪肝、非酒精性脂肪性肝炎(NASH)、炎症性自身免疫性疾病、克罗恩病、多发性硬化、动脉粥样硬化、肾脏疾病(包括慢性肾脏疾病)、肝癌和结肠癌以及其他疾病。这些化合物属于亚硫酸类化合物,可以是其对映体、立体异构体、同分异构体、溶解物、水合物、原药、代谢物或药学上可接受的盐。此外,还提供了包括此类化合物的组合物以及制备本发明化合物的方法及其用途。